Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Mid-Atlantic BioTherapeutics (MABT) logo — MABT: Impacting disease with innovative treatments.

Mid-Atlantic BioTherapeutics (MABT)

MABT: Impacting disease with innovative treatments.

Founded 2011 United States United States 4 employees Venture round Total: $5.00M Life Sciences, Pharmaceutical

General Information

Company Name Mid-Atlantic BioTherapeutics (MABT)
Founded Year 2011
Location United States United States
Employees 4
Industries Life Sciences, Pharmaceutical
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Mid-Atlantic BioTherapeutics (MABT). To contact Mid-Atlantic BioTherapeutics (MABT), visit mabt.us.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Mid-Atlantic BioTherapeutics (MABT)

Mid-Atlantic BioTherapeutics (MABT) is a clinical-stage pharmaceutical company based in the United States, founded in 2011 with a focus on eradicating infectious diseases. The company utilizes a pioneering technology platform called IMT504, which harnesses the body’s immune response to combat challenging infections. With impressive results in animal safety and efficacy models, as well as in humans, IMT504 stands out as a proprietary, revolutionary molecule with a strong safety and immunostimulatory profile. As a leader in immunotherapy for infectious diseases, MABT plays a vital role in addressing antibiotic resistance, providing an alternative to existing treatments for viral conditions such as influenza, and contributing to biodefense efforts. Notably, the company has received Orphan Drug Designation for late-stage rabies disease, offering a unique pathway to FDA approval and extended market exclusivity. MABT's groundbreaking technology has attracted significant funding, with the founders having invested over $23M to date. The most recent investment of $5.00M came from SMITM Capital Markets in a Venture Round in June 19, 2024. Through their continued investment, MABT aims to advance its innovative therapies and make a meaningful impact on disease treatment.

Taxonomy: Immunotherapy, Biopharmaceuticals, Infectious Diseases, Antibiotic Resistance, Clinical Development, Drug Commercialization, Therapeutic Innovation, Rabies Therapy, Orphan Drug Designation, Biodefense, Viral Diseases, Healthcare Innovation

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round Mid $5.00M 1
SMITM Capital Markets
19 Jun 2024

Mid-Atlantic BioTherapeutics (MABT) Alternatives & Competitors

Mid-Atlantic BioTherapeutics (MABT) vs
SciTech Development, Inc.
SciTech Development, Inc. United States

SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing breakthrough cancer...

Venture round
8 employees
Biotechnology, Life Sciences
Mid-Atlantic BioTherapeutics (MABT) vs
KYAN Therapeutics
KYAN Therapeutics

Advanced AI for Faster, Safer Drug Development and Optimized Therapies

Seed
2-10 employees
AI, Biopharma
Mid-Atlantic BioTherapeutics (MABT) vs
Emmaus Life Sciences, Inc
Emmaus Life Sciences, Inc United States

Improving the lives of people with rare disease.

Seed
36 employees
Biopharma, Biotechnology

FAQ About Mid-Atlantic BioTherapeutics (MABT)

MABT: Impacting disease with innovative treatments.
Mid-Atlantic BioTherapeutics (MABT) was founded in 2011.
Mid-Atlantic BioTherapeutics (MABT) is headquartered in United States.
Mid-Atlantic BioTherapeutics (MABT) operates in Life Sciences and Pharmaceutical. Its work centres on Immunotherapy, Biopharmaceuticals, Infectious Diseases and Antibiotic Resistance.
Mid-Atlantic BioTherapeutics (MABT) has approximately 4 employees.
Mid-Atlantic BioTherapeutics (MABT) has completed 1 funding round, raising a total of $5.00M. The latest funding stage is Venture round.
Top alternatives and competitors to Mid-Atlantic BioTherapeutics (MABT) include SciTech Development, Inc., KYAN Therapeutics, Emmaus Life Sciences, Inc, Engrail Therapeutics, Arcellx. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Mid-Atlantic BioTherapeutics (MABT) and SciTech Development, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Mid-Atlantic BioTherapeutics (MABT), https://bouncewatch.com/company/mid-atlantic-biotherapeutics-mabt, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes